Antimycobacterial agent

This page covers all Antimycobacterial agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Arabinosyl transferases (EmbA, EmbB, EmbC), InhA (enoyl-ACP reductase); KatG (catalase-peroxidase), InhA (enoyl-ACP reductase).

Targets

Arabinosyl transferases (EmbA, EmbB, EmbC) · InhA (enoyl-ACP reductase); KatG (catalase-peroxidase) · InhA (enoyl-ACP reductase) · Mycobacterial DNA; reactive oxygen species generation · Enoyl-ACP reductase (InhA), Catalase-peroxidase (KatG)

Marketed (3)

• Ethambutol (E) · University College, London · Infectious Disease
  Ethambutol inhibits mycobacterial arabinosyl transferases, disrupting the synthesis of the arabinogalactan component of the mycobacterial cell wall.
• Preventive treatment with Isoniazid · Hospital Universitari de Bellvitge · Infectious Disease
  Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, thereby killing or stopping the growth of Mycobacterium tuberculosis.
• INH preventive therapy · Johns Hopkins University · Infectious Disease
  Isoniazid (INH) preventive therapy inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, preventing the development of active tuberculosis in latently infected individuals.

Phase 3 pipeline (2)

• Clofazimine Oral Product · Wits Health Consortium (Pty) Ltd · Infectious Disease
  Clofazimine is a lipophilic antimycobacterial agent that generates reactive oxygen species and intercalates into mycobacterial DNA, disrupting bacterial replication and causing bacterial cell death.
• Isoniazid Oral Product · Wits Health Consortium (Pty) Ltd · Infectious Disease
  Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, which is essential for Mycobacterium tuberculosis survival.